
Please try another search
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Jake Simson | 38 | 2021 | Independent Director |
Greg Weiss | - | - | Member of Scientific Advisory Board |
Mark M. Davis | - | - | Member of Scientific Advisory Board |
Vickie L. Capps | 62 | 2021 | Independent Director |
David Alan Campbell | 64 | 2017 | President, CEO & Director |
Sheila K. Gujrathi | 55 | 2021 | Independent Director |
Ronald W. Barrett | 69 | 2021 | Independent Chairperson |
Alana B. McNulty | 62 | 2021 | Independent Director |
Natasha A. Hernday | 53 | 2024 | Independent Director |
Eric L. Dobmeier | 56 | 2024 | Independent Director |
Winston Kung | 49 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review